Last reviewed · How we verify
20-valent pneumococcal conjugate vaccine (20vPnC) — Competitive Intelligence Brief
marketed
Infectious Disease
Vaccine
Live · refreshed every 30 min
Target snapshot
20-valent pneumococcal conjugate vaccine (20vPnC) (20-valent-pneumococcal-conjugate-vaccine-20vpnc) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 20-valent pneumococcal conjugate vaccine (20vPnC) TARGET | 20-valent-pneumococcal-conjugate-vaccine-20vpnc | Pfizer Inc. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 20-valent pneumococcal conjugate vaccine (20vPnC) CI watch — RSS
- 20-valent pneumococcal conjugate vaccine (20vPnC) CI watch — Atom
- 20-valent pneumococcal conjugate vaccine (20vPnC) CI watch — JSON
- 20-valent pneumococcal conjugate vaccine (20vPnC) alone — RSS
Cite this brief
Drug Landscape (2026). 20-valent pneumococcal conjugate vaccine (20vPnC) — Competitive Intelligence Brief. https://druglandscape.com/ci/20-valent-pneumococcal-conjugate-vaccine-20vpnc. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab